only ) which would mean that no prescription would be required so long as :
1 . The CBD is either plant-derived , or when synthetic , is subject to certain conditions ;
2 . The maximum recommended dose is 60 mg or less ;
3 . The product is in packs containing not more than 30 days ’ supply ;
4 . CBD comprises 98 % or more of the total cannabinoid content of the preparations ;
5 . Any cannabinoids , other than CBD , must be only those naturally found in cannabis and comprise 2 % or less of the total cannabinoid content of the preparation ; and
6 . The product is for adults 18 and over .
The consultation document relating to this proposal states that “ A safety review conducted by the Therapeutic Goods Authority has established that low doses of CBD may have possible clinical utility when used via the oral route in the management of some conditions , that do not require medical practitioner oversight ”. ( 8 )
The proposal advises that the current controls in Australia are much more restrictive than those for comparable regulators in other jurisdictions , with CBD products available over the counter in the
Investor Report Industrial Hemp Sector New Zealand ’ s New Export Opportunity 2020
United Kingdom and in some US states .
The argument for keeping the products as pharmacist only , compared to freely over the counter ( OTC ), is that they consider this to be more appropriate as pharmacist advice is necessary to mitigate safety risks associated with CBD ’ s potential for drug-drug interactions when used at the same time as many other commonly prescribed drugs . Schedule 3 also requires that Product Information and Consumer Medicine Information is available to reinforce the safe use of CBD . ( 9 )
These proposals are presently being considered by the Advisory Committees of Medical Scheduling and Chemical Scheduling .
This initiative in Australia is of particular relevance to New Zealand , where there is substantial impetus in the hemp industry , to definitively remove CBD extracts from the Misuse of Drugs Act 1975 ( MoDA ).
UNITED STATES
As of 2019 , 22 states across the US have legalised medical use cannabis , and a further 11 states have broadened to allow adult-use of cannabis , for recreational and other uses . An additional 15 states allow the sale of some form of CBD oil , and of low
THC products for medical purposes .
Federally , recreational and medicinal use of cannabis containing THC remains illegal , as well as transporting cannabis across state borders .
However , there has been an important change in the federal attitude to ( non-THC ) hemp , as compared to cannabis . This change is manifested by relevant provisions in the Farm Bill of 2018 .
In 2018 the Hemp Farming Act removed hemp ( with less than 0.3 % THC ) from Schedule 1 Controlled Substances and made it an ordinary agricultural commodity .
Its provisions were incorporated in the 2018 US Farm Bill , which became law at the end of that year .
Usually the Farm Bills provide important agricultural and nutritional policy extensions for five years ; however cannabis is not typically part of the discussion around farm subsidies , nutritional assistance and crop insurance . Then , in 2018 , it was .
For decades , federal law did not differentiate hemp from other cannabis plants , all of which were in effect made illegal in 1937 under the Marihuana Tax Act , and formally made illegal in 1970 under the
25